First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Institut Bergonié
Mayo Clinic
M.D. Anderson Cancer Center
CureOne
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
Vanderbilt-Ingram Cancer Center